Beta Drugs Limited (NSE)
Source: Beta Drugs Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Beta Drugs Limited stands as an integrated specialty pharmaceutical manufacturer headquartered in northern India, dedicated primarily to the development, manufacturing, and commercialisation of cytotoxic oncology medicines, complex Active Pharmaceutical Ingredients (APIs), and specialized supportive care solutions. Operating in an industry characterized by stringent regulatory oversight and complex chemical synthesis, the company has positioned itself as an integrated oncology partner capable of synthesizing high-potency molecules from basic chemical intermediates up to finished dosage forms, including lyophilized injectables, tablets, capsules, and oral suspensions.
- Injectable Formulations (Liquid & Lyophilized): Sterile cytotoxic vials manufactured under negative-pressure isolation suites, including chemotherapy staples and complex targeted therapies.
- Oral Solid Formats (Tablets & Capsules): Highly potent oral targeted oncology molecules manufactured under dedicated high-containment tablet pressing and encapsulation suites.
- Novel Oral Suspensions: First-of-its-kind oral oncology suspensions in India designed to address dysphagia and improve pediatric/geriatric patient compliance in cancer chemotherapy.
- Oncology APIs: High-potency active substances synthesized at the Derabassi facility, supporting internal formulation self-sufficiency and third-party global B2B contracts.
📋 Quick Facts / Company Snapshot: Beta Drugs Limited (NSE)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Beta Drugs Limited |
| Corporate Identity Number (CIN) | L24230HP2005PLC028969 |
| ISIN | INE351Y01019 |
| Stock Exchange Listing | National Stock Exchange of India Limited (NSE Main Board w.e.f. November 24, 2025; Migrated from NSE SME Emerge) |
| Date of Incorporation / Production Commencement | 2005 |
| Registered Office | Village Nandpur, Lodhimajra Road, Baddi, District Solan, Himachal Pradesh – 174101, India |
| Corporate Office | SCO-184, Sector-5, Panchkula, Haryana – 134114, India |
| Telephone & Investor Contact | 0172-2585481, 482, 483 | Email: cs@betadrugslimited.com |
| Executive Leadership | Mr. Rahul Batra (Chairman & Managing Director) | Mr. Varun Batra (Joint Managing Director) |
| Key Managerial Personnel (KMP) | Mr. Nipun Arora (Chief Financial Officer) | Mrs. Rajni Brar (Company Secretary & Compliance Officer) |
| Promoter Group | Batra Family (Mrs. Neeraj Batra, Mr. Rahul Batra, Mr. Varun Batra, Mrs. Heena Batra, Mrs. Aditi Batra) |
| Industry / Sector Classification | Pharmaceuticals & Life Sciences (Specialty Oncology, Active Pharmaceutical Ingredients, Dermatology & IVF Therapies) |
| Permanent Workforce | 455 permanent employees on the rolls as of March 31, 2026 |
| Core Operational Footprint | Formulation Manufacturing Unit (Baddi, Himachal Pradesh), API Synthesis Facility (Adley Lab, Derabassi, Punjab), Formulation Facility (Adley Formulations, Kotla, Barotiwala, Himachal Pradesh) |
| Credit Ratings (Brickwork Ratings) | Long-term Bank Loan Facilities: BWR A-/Stable | Short-term Bank Loan Facilities: BWR A2 |
| Statutory Auditors | M/s Khurana Sharma & Company, Chartered Accountants, Chandigarh (FRN: 010920N) |
| Secretarial Auditor | Mr. Dinesh Bhandari, Practising Company Secretary, Chandigarh (FCS No. 5887, CP No. 10300) |
| Cost Auditor | M/s Charu Jindal & Company, Cost Accountants, Dehradun (FRN: 103508) |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Private Limited, C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai – 400083 |
🏢 The Corporate Identity: Beta Drugs Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Beta Drugs Limited stands as an integrated specialty pharmaceutical manufacturer headquartered in northern India, dedicated primarily to the development, manufacturing, and commercialisation of cytotoxic oncology medicines, complex Active Pharmaceutical Ingredients (APIs), and specialized supportive care solutions. Operating in an industry characterized by stringent regulatory oversight and complex chemical synthesis, the company has positioned itself as an integrated oncology partner capable of synthesizing high-potency molecules from basic chemical intermediates up to finished dosage forms, including lyophilized injectables, tablets, capsules, and oral suspensions.
The company operates across a dual-engine commercial model encompassing its proprietary branded domestic oncology formulation business and a high-volume institutional contract manufacturing and supply business. Within the domestic market, Beta Drugs markets its own portfolio of branded generics directly to cancer institutions, tertiary healthcare networks, and medical oncologists. Concurrently, the group functions as a trusted manufacturing partner supplying critical anti-cancer drugs to top-tier domestic pharmaceutical companies and government tenders, underpinned by an expanding international footprint spanning semi-regulated and emerging regulated export territories.
A central pillar of Beta Drugs’ value proposition is backward integration into active pharmaceutical ingredients through its wholly owned subsidiary, Adley Lab Limited. By producing approximately 70% of its API requirements internally, the enterprise insulates its manufacturing pipeline from global supply-chain shocks, mitigates dependency on imported raw materials, protects cost structures, and accelerates speed-to-market for novel generic and Novel Drug Delivery System (NDDS) formulations.
The Founders, Promoters & Their Legacy
The entrepreneurial foundation of Beta Drugs Limited is steered by the Batra family, who have established deep technical and managerial roots within the Indian pharmaceutical industry over several decades. Chairman and Managing Director Mr. Rahul Batra and Joint Managing Director Mr. Varun Batra direct the strategic, corporate finance, international expansion, and operational policies of the enterprise.
Promoter equity ownership is concentrated primarily through Mrs. Neeraj Batra, who holds 64,73,631 equity shares representing 63.86% of the company’s paid-up equity capital as of March 31, 2026. The total promoter and promoter group shareholding stands at 64.63%, representing 65,51,392 equity shares. Both executive promoters bring complementary professional training: Mr. Rahul Batra holds a Master of Science degree in Business and Management from the University of Strathclyde, Scotland, bringing 20 years of sector experience, while Mr. Varun Batra holds a degree in Business Management from Toronto, Canada, also contributing two decades of operational and supply-chain management expertise.
- Mr. Rahul Batra (Chairman & Managing Director): Responsible for corporate governance, strategic capital allocation, research partnerships, and business development across domestic and global markets.
- Mr. Varun Batra (Joint Managing Director): Leads plant infrastructure, supply chain operations, internal controls, and execution of manufacturing capital expenditures.
- Promoter Stability: Unencumbered promoter ownership exceeding 64% underscores strong long-term alignment between executive leadership and public market stakeholders.
The Journey: Corporate History & Key Milestones
Commencing commercial production in 2005 at Baddi in Himachal Pradesh, Beta Drugs Limited began as a regional formulation manufacturer before focusing on the high-barrier therapeutic segment of oncology. Identifying the acute scarcity of high-quality, indigenously manufactured cytotoxic therapies, the company directed substantial capital into cleanroom technology, sterile containment, and barrier-isolation manufacturing lines designed to handle toxic compounds safely.
A transformative transition occurred during FY 2018-19, when Beta Drugs initiated backward integration by absorbing and scaling API synthesis capabilities, creating dedicated oncology API assets. In subsequent years, the group diversified into specialized subsidiaries: incorporating Adley Formulations Private Limited in October 2018 to ramp up oral solid and liquid formulation capacity, and consolidating Adley Lab Limited to spearhead high-potency oncology API manufacturing. In 2021, Beta Research Private Limited was incorporated to advance formulation R&D.
Capital market milestones accelerated between 2024 and 2026. On November 24, 2025, Beta Drugs officially migrated its equity shares from the NSE SME Emerge platform to the Main Board of the National Stock Exchange of India Limited. In January 2026, the Board approved the landmark acquisition of a 66.09% majority stake in Mumbai-based Nivian Lifesciences Private Limited for ₹69.40 Crores, consummated in April 2026, marking the group’s strategic entry into the fast-growing In-Vitro Fertilisation (IVF), assisted reproductive technology (ART), and women’s health sector.
The Corporate Umbrella & Group Structure
The corporate umbrella of Beta Drugs Limited encompasses three operating wholly owned subsidiaries as of March 31, 2026, alongside a post-balance sheet majority-controlled subsidiary:
- Adley Formulations Private Limited (100% Owned Subsidiary): Incorporated on October 9, 2018, operating an advanced formulation facility at Kotla, Barotiwala, District Solan, Himachal Pradesh. The company manufactures and trades finished oncology formulations, generating ₹141.17 Crores in revenue during FY 2025-26.
- Adley Lab Limited (100% Owned Subsidiary): Incorporated on April 10, 1992, based at D-27, Industrial Area Focal Point, Derabassi, Punjab. It serves as the group’s active pharmaceutical ingredient engine, synthesizing high-value cytotoxic APIs with a standalone turnover of ₹80.23 Crores in FY 2025-26.
- Beta Research Private Limited (100% Owned Subsidiary): Corporate office in Panchkula, Haryana, incorporated to serve as a specialized vehicle for clinical trials, NDDS patents, and technology transfers. It had no commercial operations during the year under review.
- Nivian Lifesciences Private Limited (66.09% Majority Acquisition): Headquartered in Thane, Maharashtra, acquired in April 2026 for ₹69.40 Crores (funded via ₹20.82 Crores cash and ₹48.58 Crores via the allotment of 2,83,668 equity shares at ₹1,712.49 per share) to drive branded formulation expansion into IVF, fertility hormones, and reproductive care.
⚙️ The Business Engine: Beta Drugs Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Consolidated revenue from operations for FY 2025-26 reached ₹384.83 Crores, representing a 6.20% year-on-year expansion against ₹362.36 Crores in FY 2024-25. The company’s operational performance reflects deliberate segment exposure: the Oncology division forms the dominant earnings driver, complemented by the emerging Dermatology segment and the newly added IVF division.
| Business Segment / Division | Segment Revenue FY 2025-26 (₹ Crores) | Segment Revenue FY 2024-25 (₹ Crores) | % Share of Total FY 2025-26 Revenue | Operational EBITDA Margin (%) | Latest YoY (%) |
|---|---|---|---|---|---|
| Oncology Formulations & Active Ingredients | 374.00 | 352.00 | 97.19% | 20.60% | +6.25% |
| Dermatology & Cosmetology Products | 10.83 | 10.36 | 2.81% | Breakeven (0.00%) | +4.54% |
| Total Consolidated Operations | 384.83 | 362.36 | 100.00% | 19.67% | +6.20% |
Operational EBITDA excluding other income stood at ₹75.70 Crores on a consolidated basis, yielding an EBITDA margin of 19.67%. The core oncology business delivered an EBITDA margin of 20.60%, demonstrating the profitability of cytotoxic manufacturing. Meanwhile, the dermatology division achieved operational breakeven at the EBITDA level during FY 2025-26, laying the groundwork for positive operating leverage as brand penetration deepens.
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
Beta Drugs maintains a diversified oncology formulation catalog spanning multiple dosage formats designed to serve acute oncology regimens:
- Injectable Formulations (Liquid & Lyophilized): Sterile cytotoxic vials manufactured under negative-pressure isolation suites, including chemotherapy staples and complex targeted therapies.
- Oral Solid Formats (Tablets & Capsules): Highly potent oral targeted oncology molecules manufactured under dedicated high-containment tablet pressing and encapsulation suites.
- Novel Oral Suspensions: First-of-its-kind oral oncology suspensions in India designed to address dysphagia and improve pediatric/geriatric patient compliance in cancer chemotherapy.
- Oncology APIs: High-potency active substances synthesized at the Derabassi facility, supporting internal formulation self-sufficiency and third-party global B2B contracts.
- Supply Chain Sourcing Split: 70% of the active pharmaceutical ingredients required for the company’s finished formulations are produced internally, shielding operations from import volatility. Raw material chemical purchases totaled ₹185.87 Crores in FY 2025-26.
- Customer Concentration: Beta Drugs supplies branded formulations to hospital networks across India, acts as an institutional supplier to leading Indian multinational pharma companies, and services institutional tenders abroad. No single client concentration risk impaired operational continuity.
The Names You Know: Key Brands & Flagship Portfolio
Within the domestic branded oncology space, Beta Drugs has built established prescription equity across oncologists and hospital formularies, with multiple flagship brands ranking among the top five in their respective molecule categories.
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Flagship Cytotoxic Injectable Portfolio | Branded Oncology Formulations | Chemotherapy protocols across solid tumors and hematological malignancies; top-5 market share ranking in key molecules. |
| Targeted Oral Oncology Range | Oral Solid Cytotoxics (Tablets & Capsules) | Targeted kinase inhibitors and maintenance therapy prescribed across major cancer centers in India. |
| Novel Oral Suspension Line | Novel Drug Delivery Systems (NDDS) | India-first oncology suspension format providing ease of administration; ranked among Beta’s Top 10 brands in FY 2025-26. |
| Dermatology & Cosmetology Formulations | Cosmetic Dermatology & Skin Health | Prescription dermatologicals and therapeutic skincare marketed to dermatologists and aesthetic clinics. |
| Nivian Reproductive Health Suite | In-Vitro Fertilisation & ART Products | Specialty fertility therapies, hormones, and assisted reproduction portfolio entering the group umbrella via acquisition. |
Mapping the Domestic & Global Reach (India vs. Exports)
Beta Drugs commands an extensive domestic distribution network while expanding its presence across semi-regulated and emerging regulated global pharmaceutical markets. FY 2025-26 consolidated revenue demonstrates balanced domestic stability alongside active international registration activity.
| Geographic Revenue Segment | FY 2025-26 Revenue (₹ Crores) | FY 2024-25 Revenue (₹ Crores) | % Share of Total FY 2025-26 Revenue | Latest YoY (%) |
|---|---|---|---|---|
| Domestic Sales (India) | 313.96 | 282.87 | 81.58% | +10.99% |
| Export Sales (International) | 70.87 | 79.48 | 18.42% | -10.83% |
| Total Revenue from Operations | 384.83 | 362.36 | 100.00% | +6.20% |
Domestic formulation sales expanded by 10.99% YoY from ₹282.87 Crores to ₹313.96 Crores, driven by robust prescription demand in oncology. Export revenues experienced a modest contraction of 10.83% YoY from ₹79.48 Crores to ₹70.87 Crores due to tender delays in select overseas markets and prolonged registration timelines influenced by geopolitical complexities. In actual foreign exchange inflows, the company earned ₹67.75 Crores in FY 2025-26 compared to ₹63.79 Crores in FY 2024-25. The company is actively building momentum with a pipeline exceeding 600 cumulative dossier filings targeted across FY 2026-27 and FY 2027-28 in semi-regulated and regulated markets, including Europe.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The manufacturing and technical infrastructure of Beta Drugs Limited is strategically clustered in northern India to optimize logistics and supervisory oversight:
- Baddi Manufacturing Facility (Himachal Pradesh): Located at Village Nandpur, Lodhimajra Road, Baddi, District Solan. Houses the group’s central formulation plants, sterile injectable containment suites, oral solid dosage lines, and quality control laboratories.
- Adley Formulations Facility (Himachal Pradesh): Situated at Kotla, Barotiwala, District Solan. Operates as a specialized finished dosage manufacturing center equipped for high-throughput commercial packing and batch synthesis.
- Adley Lab API Synthesis Center (Derabassi, Punjab): Located at D-27, Industrial Area Focal Point, Derabassi, District SAS Nagar (Mohali). Serves as the high-potency chemical synthesis center producing oncology APIs and Key Starting Materials (KSMs).
- Corporate & Administrative Headquarters: SCO-184, Sector-5, Panchkula, Haryana, housing executive leadership, finance, legal, regulatory affairs, and commercial marketing operations.
📊 The Financial Health: Beta Drugs Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
A multi-year analysis illustrates the compounding trajectory of Beta Drugs Limited across standalone and consolidated operations as backward integration and marketing investments bore fruit.
| Financial Metric | Consolidated FY 2025-26 | Consolidated FY 2024-25 | Standalone FY 2025-26 | Standalone FY 2024-25 | Latest YoY (%) |
|---|---|---|---|---|---|
| Revenue from Operations | 384.83 | 362.36 | 225.43 | 220.20 | +6.20% |
| Other Income | 11.18 | 6.44 | 11.14 | 6.19 | +73.60% |
| Total Income | 396.01 | 368.79 | 236.57 | 226.39 | +7.38% |
| Operating EBITDA (excl. Other Income) | 75.70 | 74.60 | 27.88 | 32.85 | +1.47% |
| Depreciation & Amortisation | 17.15 | 12.51 | 9.67 | 7.44 | +37.09% |
| Finance Costs | 15.31 | 6.99 | 10.02 | 3.50 | +119.03% |
| Profit Before Tax (PBT) | 54.39 | 56.97 | 18.21 | 20.84 | -4.53% |
| Profit After Tax (PAT) | 41.48 | 42.42 | 14.33 | 15.43 | -2.22% |
| Total Comprehensive Income | 41.66 | 42.42 | 14.33 | 15.43 | -1.79% |
| Total Equity (Net Worth) | 244.77 | 197.10 | 184.14 | 163.50 | +24.19% |
| Total Assets | 495.80 | 436.23 | 352.12 | 316.54 | +13.66% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
Consolidated total income for the financial year ended March 31, 2026, expanded to ₹396.01 Crores compared to ₹36.88 Crores in FY 2024-25. Profit before tax stood at ₹54.39 Crores, with final profit after tax attributable to equity shareholders recorded at ₹41.48 Crores.
| Particulars (Consolidated Statement of Profit and Loss) | Note | FY 2025-26 (₹ Crores) | FY 2024-25 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|---|
| I. Income | ||||
| Revenue from operations (net) | 20 | 384.83 | 362.36 | +6.20% |
| Other income | 21 | 11.18 | 6.44 | +73.60% |
| Total Income (I) | 396.01 | 368.79 | +7.38% | |
| II. Expenses | ||||
| Cost of materials consumed | 22 | 173.81 | 175.78 | -1.12% |
| Purchases of stock-in-trade | 0.00 | 0.00 | N/M | |
| Changes in inventories of finished goods, WIP and stock-in-trade | 23 | -2.63 | -4.42 | -40.50% |
| Employee benefits expense | 24 | 68.01 | 55.51 | +22.52% |
| Finance costs | 25 | 15.31 | 6.99 | +119.03% |
| Depreciation and amortisation expense | 1 | 17.15 | 12.51 | +37.09% |
| Other expenses | 26 | 69.96 | 60.88 | +14.91% |
| Total Expenses (II) | 341.61 | 307.25 | +11.18% | |
| Profit Before Exceptional Items and Tax (I − II) | 54.39 | 61.54 | -11.62% | |
| Exceptional items | 0.00 | 4.57 | -100.00% | |
| Profit Before Tax | 54.39 | 56.97 | -4.53% | |
| Current tax | 13.66 | 14.97 | -8.75% | |
| Deferred tax | -0.75 | -0.42 | +78.57% | |
| Total tax expense | 12.91 | 14.55 | -11.27% | |
| Profit for the Year Attributable to Owners | 41.48 | 42.42 | -2.22% | |
| Other Comprehensive Income | ||||
| Remeasurement gain on defined benefit plans (net of tax) | 0.18 | 0.00 | N/M | |
| Total Comprehensive Income for the Year | 41.66 | 42.42 | -1.79% | |
| Basic Earnings Per Share (₹) | 40.92 | 42.02 | -2.62% | |
| Diluted Earnings Per Share (₹) | 40.92 | 42.02 | -2.62% | |
Cost of materials consumed moderated slightly to ₹173.81 Crores against ₹175.78 Crores in the preceding fiscal, reflecting supply efficiency from backward integration. However, finance costs increased to ₹15.31 Crores from ₹6.99 Crores, primarily driven by ₹9.36 Crores in interest charges on compulsorily convertible debentures (CCDs) issued during the preceding year to fund strategic growth. Employee expenses rose from ₹55.51 Crores to ₹68.01 Crores as talent was expanded across formulation R&D and field sales.
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
As of March 31, 2026, Beta Drugs commanded a consolidated asset base of ₹495.80 Crores supported by an equity net worth of ₹244.77 Crores. The balance sheet reflects sizable capital expenditure in physical manufacturing assets alongside substantial liquidity reserves.
| Particulars (Consolidated Balance Sheet) | Note | As at March 31, 2026 (₹ Crores) | As at March 31, 2025 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|---|
| A. Non-Current Assets | ||||
| Property, Plant and Equipment | 1 | 115.37 | 80.36 | +43.57% |
| Intangible assets | 1 | 9.90 | 8.57 | +15.52% |
| Capital work-in-progress | 0.00 | 0.00 | N/M | |
| Other non-current financial assets | 2 | 17.96 | 14.14 | +27.02% |
| Deferred tax assets (net) | 3 | 2.52 | 1.83 | +37.70% |
| Other non-current assets | 4 | 14.90 | 10.94 | +36.20% |
| Total Non-Current Assets | 160.64 | 115.85 | +38.66% | |
| B. Current Assets | ||||
| Inventories | 5 | 74.46 | 59.77 | +24.58% |
| Trade receivables | 6 | 119.13 | 102.58 | +16.13% |
| Cash and cash equivalents | 7 | 124.85 | 147.02 | -15.08% |
| Other current financial assets | 8 | 15.45 | 9.31 | +65.95% |
| Other current assets | 9 | 1.27 | 1.70 | -25.29% |
| Total Current Assets | 335.16 | 320.39 | +4.61% | |
| TOTAL ASSETS | 495.80 | 436.23 | +13.66% | |
| C. Equity | ||||
| Equity share capital | 10 | 10.14 | 10.09 | +0.50% |
| Other equity (Reserves & Surplus) | 11 | 234.63 | 187.00 | +25.47% |
| Total Equity | 244.77 | 197.10 | +24.19% | |
| D. Non-Current Liabilities | ||||
| Non-current borrowings | 12 | 133.32 | 126.99 | +4.98% |
| Long-term provisions | 13 | 2.81 | 2.56 | +9.77% |
| Other non-current liabilities | 14 | 6.75 | 6.83 | -1.17% |
| Total Non-Current Liabilities | 142.89 | 136.38 | +4.77% | |
| E. Current Liabilities | ||||
| Current borrowings | 15 | 14.48 | 11.06 | +30.92% |
| Trade payables | 16 | 80.63 | 71.28 | +13.12% |
| Other current financial liabilities | 17 | 1.50 | 10.93 | -86.28% |
| Short-term provisions | 18 | 5.74 | 4.31 | +33.18% |
| Other current liabilities | 19 | 5.79 | 5.18 | +11.78% |
| Total Current Liabilities | 108.14 | 102.76 | +5.24% | |
| Total Liabilities | 251.03 | 239.14 | +4.97% | |
| TOTAL EQUITY AND LIABILITIES | 495.80 | 436.23 | +13.66% | |
Property, Plant and Equipment climbed from ₹80.36 Crores to ₹115.37 Crores, driven by additions in industrial land, sterile manufacturing suites, and advanced lab equipment. Within non-current borrowings of ₹133.32 Crores, ₹110.00 Crores represents 7.8% compulsorily convertible debentures (CCDs), while secured bank term loans account for ₹23.32 Crores. With consolidated cash and cash equivalents of ₹124.85 Crores, Beta Drugs operates in a net debt-free position when excluding convertible debenture instruments.
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Operational working capital management remained resilient during the year, supported by disciplined debtor tracking and liquidity deployment across short-term bank deposits.
| Operational & Financial Ratio | FY 2025-26 | FY 2024-25 | Variance (%) | Statutory Explanation for Variance >25% | Latest YoY (%) |
|---|---|---|---|---|---|
| Debtors Turnover Ratio | 4.40 | 4.45 | -1.12% | Trade receivable collections remained in line with historic operating velocity. | -1.12% |
| Inventory Turnover Ratio | 5.01 | 5.73 | -12.56% | Moderate inventory accumulation in raw materials to safeguard production runs. | -12.57% |
| Interest Coverage Ratio | 2.54 | 5.38 | -52.78% | EBIT increased by ₹4.42 Crores, but Interest Expense surged by ₹7.05 Crores due to debenture coupon costs. | -52.79% |
| Current Ratio | 4.02 | 4.18 | -3.82% | Liquidity profile remained highly comfortable with current assets exceeding liabilities 4-fold. | -3.83% |
| Debt-Equity Ratio | 0.90 | 1.02 | -11.76% | Modest deleveraging aided by profit accumulation in reserves and surplus. | -11.76% |
| Operating Profit Margin (%) | 13.00% | 11.62% | +11.87% | Benefited from backward integration into APIs and formulation cost discipline. | – |
| Net Profit Margin (%) | 41.48 | 7.01% | -14.40% | Impacted by higher debenture financing costs and expanded depreciation charges. | – |
| Return on Equity (ROE) (%) | 16.95% | 21.52% | -16.38% | Expanded equity base following earnings retention and preferential conversions. | – |
Cash Flow: Tracking the Money Movement
Cash flows generated from operational activities stood at ₹37.29 Crores during FY 2025-26, highlighting underlying cash generation before working capital adjustments and tax disbursements.
| Particulars (Consolidated Cash Flow Statement) | FY 2025-26 (₹ Crores) | FY 2024-25 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| A. Cash Flow from Operating Activities | |||
| Net profit before tax and extraordinary items | 41.48 | 61.54 | -32.60% |
| Adjustments: Depreciation and amortisation | 17.15 | 12.51 | +37.09% |
| Adjustments: Finance costs | 15.31 | 6.99 | +119.03% |
| Adjustments: Interest received | -9.86 | -5.11 | +92.95% |
| Adjustments: Other non-cash inflows / outflows | -12.72 | -20.76 | -38.73% |
| Operating Profit Before Working Capital Changes | 64.27 | 55.17 | +16.49% |
| (Increase) / decrease in trade receivables | -16.55 | -23.34 | -29.09% |
| Increase / (decrease) in trade payables | 9.35 | 11.98 | -21.95% |
| (Increase) / decrease in inventories | -14.69 | -9.96 | +47.49% |
| Increase / (decrease) in other current liabilities | 0.61 | 3.81 | -83.99% |
| (Increase) / decrease in short-term loans and advances | -6.14 | -2.16 | +184.26% |
| (Increase) / decrease in other current assets | 0.43 | 0.64 | -32.81% |
| Net working capital changes | -26.99 | -19.03 | +41.83% |
| Net Cash Flow from Operating Activities (A) | 37.29 | 36.14 | +3.18% |
| B. Cash Flow from Investing Activities | |||
| Purchase of tangible / intangible assets (CapEx) | 53.48 | 36.86 | +45.09% |
| Interest received | 9.86 | 5.11 | +92.95% |
| Cash used for long-term loans / advances | -7.77 | -3.97 | +95.72% |
| Net Cash Used in Investing Activities (B) | -51.39 | -35.72 | +43.87% |
| C. Cash Flow from Financing Activities | |||
| Finance costs paid | -15.31 | -6.99 | +119.03% |
| Increase / (repayment) of short-term borrowings | -6.01 | 0.76 | N/M |
| Increase / (repayment) of long-term borrowings | 6.33 | 123.72 | -94.88% |
| Increase / (repayment) of other long-term liabilities | -0.08 | 0.00 | N/M |
| Proceeds from issue of share capital & securities premium | 7.00 | 0.48 | +1358.33% |
| Net Cash Generated from / (Used in) Financing Activities (C) | -8.07 | 117.97 | N/M |
| Net Increase / (Decrease) in Cash and Cash Equivalents | -22.18 | 118.39 | N/M |
| Cash and cash equivalents at the beginning of the year | 147.02 | 28.63 | +413.52% |
| Cash and cash equivalents at the end of the year | 124.85 | 147.02 | -15.08% |
Investing outflows totaled ₹51.39 Crores, predominantly absorbed by ₹53.48 Crores in property, plant, and equipment additions and product dossier registrations. Financing outflows reflected interest servicing of ₹15.31 Crores and net debt adjustments, resulting in a cash and cash equivalent balance of ₹124.85 Crores at fiscal year-end, consisting of fixed deposits and operational balances across commercial banks.
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Beta Drugs allocated substantial financial resources during FY 2025-26 toward infrastructure scaling, backward integration, and proprietary laboratory product development:
- API Synthesis CapEx: Invested ₹10.45 Crores in FY 2025-26 toward expanding the Derabassi active ingredient facility, with a further planned deployment of ₹25.00 Crores to manufacture key starting materials locally by Q3 FY 2026-27.
- Monitoring Preferential Issue Proceeds: Out of ₹117.01 Crores mobilized via preferential equity and CCDs, ₹23.87 Crores was utilized through March 31, 2026 (including ₹2.25 Crores at Adley Formulations, ₹1.35 Crores at Adley Lab, ₹0.95 Crores in R&D setup, ₹9.52 Crores in manufacturing expansion, and ₹9.80 Crores in general corporate purposes), leaving ₹93.13 Crores in unutilized funds monitored by Brickwork Ratings India Private Limited.
- R&D Expenditure: Direct standalone research and development expenditure incurred stood at ₹2.04 Crores, supplemented by ₹3.59 Crores in R&D consumable chemical stores and ₹0.31 Crores in dedicated scientist payroll.
- Net Foreign Exchange Earnings: Total foreign exchange earned through direct exports reached ₹67.75 Crores, whereas total foreign exchange consumed in raw materials and overseas outlays was ₹8.35 Crores, yielding net positive foreign exchange inflows of ₹59.40 Crores.
👥 Power & Control: Beta Drugs Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The governance structure of Beta Drugs Limited comprises ten directors, balanced between four executive directors, one non-executive investor director, and five non-executive independent directors, including one woman independent director.
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Rahul Batra | Chairman & Managing Director | 02229234 | Executive (Promoter) |
| Mr. Varun Batra | Joint Managing Director | 02148383 | Executive (Promoter) |
| Mr. Balwant Singh | Whole-Time Director | 01089968 | Executive |
| Mr. Ashutosh Shukla | Whole-Time Director (Sales & Marketing) | 09461568 | Executive |
| Mr. Ajay Mahipal | Director | 06949940 | Non-Executive (Non-Independent / HealthQuad Partner) |
| Mr. Rohit Parti | Independent Director | 07889944 | Non-Executive (Independent) |
| Mr. Manmohan Khanna | Independent Director (Audit Committee Chair) | 07888319 | Non-Executive (Independent) |
| Mr. Sanjay Sehgal | Independent Director | 01235531 | Non-Executive (Independent) |
| Mr. Lalit Kumar Watts | Independent Director | 10906518 | Non-Executive (Independent) |
| Mrs. Monica Jain | Independent Director | 05253864 | Non-Executive (Independent) |
| Mr. Nipun Arora | Chief Financial Officer | – | Key Managerial Personnel |
| Mrs. Rajni Brar | Company Secretary & Compliance Officer | – | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, the company’s total issued, subscribed, and paid-up equity share capital stood at ₹10.14 Crores, divided into 1,01,36,890 equity shares of face value ₹10 each. All shares are fully dematerialized through NSDL and CDSL.
| Shareholder Category | Number of Shares Held | % of Total Issued Equity Shares |
|---|---|---|
| Promoter & Promoter Group | 65,51,392 | 64.63% |
| Institutional Investors (AIFs, FPIs & NBFCs) | 3,31,996 | 3.27% |
| Bodies Corporate & Limited Liability Partnerships | 8,72,547 | 8.61% |
| Non-Resident Indians (NRIs & Non-Repatriable) | 97,529 | 0.96% |
| Hindu Undivided Families (HUFs) & Trusts | 52,680 | 0.52% |
| Clearing Members | 1,836 | 0.02% |
| General Public / Resident Individuals | 22,28,910 | 21.99% |
| Total Issued Equity Capital | 1,01,36,890 | 100.00% |
- Mrs. Neeraj Batra: 64,73,631 equity shares (63.86%), anchoring the promoter block.
- Mr. Rahul Batra: 41,632 equity shares (0.41%).
- Mr. Varun Batra: 34,891 equity shares (0.34%).
- Mrs. Heena Batra & Mrs. Aditi Batra: 619 equity shares each (0.01% each).
- Alternate Investment Funds (AIFs): AIF Category III vehicles hold 2,13,520 shares (2.11%) alongside AIF Category II holdings.
- Foreign Portfolio Investors: FPI Corporate Category I and II accounts collectively hold 1,16,933 shares (1.15%).
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
The corporate family tree of Beta Drugs Limited consists of wholly owned operational subsidiaries that handle specific links in the pharmaceutical value chain, from raw API synthesis to specialized formulations.
| Entity Name | Relationship | Operating Jurisdiction | % Equity Holding | FY 2025-26 Turnover (₹ Crores) | FY 2025-26 PAT (₹ Crores) |
|---|---|---|---|---|---|
| Adley Formulations Private Limited | Wholly Owned Subsidiary | Kotla, Solan, Himachal Pradesh, India | 100.00% | 141.17 | 16.66 |
| Adley Lab Limited | Wholly Owned Subsidiary | Derabassi, SAS Nagar, Punjab, India | 100.00% | 80.23 | 10.49 |
| Beta Research Private Limited | Wholly Owned Subsidiary | Panchkula, Haryana, India | 100.00% | 0.00 | 0.00 |
| Nivian Lifesciences Private Limited | Majority-Owned Subsidiary (Acquired Apr 2026) | Thane, Maharashtra, India | 66.09% | Post-Balance Sheet Acquisition | Post-Balance Sheet Acquisition |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
The company maintains long-standing credit facilities with a consortium of scheduled commercial banks and development institutions, with primary limits extended by HDFC Bank Limited and ICICI Bank Limited.
- Independent Credit Ratings: Brickwork Ratings India Private Limited has affirmed long-term bank loan facilities of the company at BWR A-/Stable and short-term debt limits at BWR A2.
- Contingent Corporate Guarantees Extended: Beta Drugs Limited has furnished corporate guarantees to lenders on behalf of its wholly owned subsidiaries, including ₹13.01 Crores to ICICI Bank for credit facilities extended to Adley Formulations Private Limited, and ₹11.50 Crores to HDFC Bank alongside ₹0.40 Crores to SIDBI on behalf of Adley Lab Limited (aggregate corporate guarantees standing at ₹24.91 Crores as of March 31, 2026).
- Inter-Company Loan Exposures: Standalone loans extended under Section 186 to Adley Lab Limited stood at ₹10.16 Crores and to Adley Formulations Private Limited stood at ₹5.82 Crores (totaling ₹15.98 Crores).
- Convertible Capital Instruments: As of March 31, 2026, 6,65,314 compulsorily convertible debentures (CCDs) remained outstanding, which were subsequently converted on a 1:1 basis into 6,65,314 fully paid equity shares of ₹10 each on May 25, 2026.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Beta Drugs operates with distinct operational moats within the Indian pharmaceutical industry, primarily derived from high technical barriers and backward supply integration:
- In-House API Backward Integration: By synthesizing 70% of its key active pharmaceutical ingredients internally through Adley Lab Limited, Beta Drugs protects gross margins and guarantees batch supply security for critical oncology hospital orders.
- High-Containment Cytotoxic Infrastructure: Designing and maintaining cGMP-compliant negative-pressure oncology containment suites requires substantial capital outlay and technical handling protocols, creating high entry barriers against non-specialized generic manufacturers.
- Clinical Differentiation via NDDS Formulations: The successful commercial launch of specialized oral oncology suspensions demonstrates proprietary formulation capabilities that improve cancer patient compliance while commanding superior pricing power over standard generic tablets.
- Established Prescriber Trust: Direct hospital marketing teams and relationships with premier oncology institutions across India have positioned Beta’s flagship molecules among the top five therapeutic brands in their respective classes.
What Could Go Wrong? Key Challenges & Business Risks
Despite its defensible oncology niche, Beta Drugs navigates several operational and regulatory risks inherent to the specialty pharmaceutical industry:
- Geopolitical & Export Tender Friction: International sales contracted 10.83% in FY 2025-26 due to administrative delays in export tenders and extended dossier review cycles across overseas regulatory bodies.
- Raw Material Commodity & Import Exposure: While backward integrated for 70% of APIs, key starting materials and chemical reagents remain exposed to international commodity price shifts and foreign currency fluctuations.
- Capital Costs of Convertible Instruments: Finance costs surged to ₹15.31 Crores during FY 2025-26 as CCD coupon interest reached ₹9.36 Crores, exerting near-term pressure on net profit margins.
- Post-Acquisition Integration: Commercialising and scaling the 66.09% acquired stake in Nivian Lifesciences requires successful execution across unfamiliar gynecological, reproductive, and IVF hospital distribution networks.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Beta Drugs has outlined an aggressive growth roadmap articulated through its “Vision 2030” strategy, unveiled in April 2026. The strategic charter aims to establish Beta Drugs as one of the top five cytotoxic oncology manufacturers in India, while building a diversified specialty presence spanning Oncology, IVF, and Dermatology.
Growth initiatives center on commissioning the ₹35.00 Crore aggregate capital expansion at the Derabassi API facility by Q3 FY 2026-27. This infrastructure will enable indigenous synthesis of key starting materials (KSMs), significantly curtailing import reliance and driving gross margin expansion. Furthermore, the company is advancing a dossier pipeline exceeding 600 filings across FY 2026-27 and FY 2027-28, creating a structural runway to capture regulated market demand in Europe and other international territories.
The Verdict: Strategic Outlook & Conclusion
Beta Drugs Limited has transitioned from an agile oncology formulation producer into a vertically integrated, multi-specialty life sciences player. Backed by a clean balance sheet featuring net cash liquidity of ₹124.85 Crores (excluding convertible debentures), 20.60% EBITDA margins in core oncology, and disciplined deployment of preferential growth capital, the enterprise possesses the operational levers and research capabilities to scale domestic market share and accelerate high-value global registrations through the close of the decade.
Frequently Asked Questions (FAQs) About Beta Drugs
Q1: What does Beta Drugs Limited manufacture and what are its flagship brands?
Beta Drugs Limited manufactures cytotoxic oncology medicines, including lyophilized and liquid injectables, oral tablets, capsules, and novel drug delivery suspensions, along with high-potency active pharmaceutical ingredients (APIs). Through subsidiaries, it produces oncology APIs (Adley Lab) and oral formulations (Adley Formulations), while expanding into IVF and reproductive healthcare through Nivian Lifesciences. Its key oncology brands hold top-5 ranks across several chemotherapy molecules in India.
Q2: What were Beta Drugs’ revenue and net profit figures in FY 2025-26?
On a consolidated Ind AS basis, Beta Drugs Limited generated revenue from operations of ₹384.83 Crores in FY 2025-26, compared to ₹362.36 Crores in FY 2024-25. Consolidated profit after tax (PAT) attributable to shareholders was ₹41.48 Crores in FY 2025-26, compared to ₹42.42 Crores in the preceding fiscal year.
Q3: Who are the primary promoters and executive leaders of Beta Drugs?
The company is led by executive promoters Mr. Rahul Batra (Chairman & Managing Director) and Mr. Varun Batra (Joint Managing Director). The promoter and promoter group hold 64.63% of the paid-up share capital, with Mrs. Neeraj Batra serving as the largest shareholder holding 63.86% of the company’s equity.
Q4: Where are the manufacturing plants located and what is the export share?
The company operates formulation facilities in Baddi and Kotla (Barotiwala) in Himachal Pradesh, and an active oncology API manufacturing center in Derabassi, Punjab. In FY 2025-26, domestic sales accounted for ₹313.96 Crores (81.58% of revenues), while export markets generated ₹70.87 Crores (18.42% of operations).
Q5: What is the company’s debt profile, credit rating, and net worth?
Beta Drugs had total equity (net worth) of ₹244.77 Crores as of March 31, 2026. Consolidated non-current borrowings stood at ₹133.32 Crores, of which ₹110.00 Crores comprised 7.8% compulsorily convertible debentures (subsequently converted in May 2026). Brickwork Ratings rates the company’s long-term bank facilities at BWR A-/Stable and short-term facilities at BWR A2. With ₹124.85 Crores in cash and cash equivalents, the company is net debt-free when excluding convertible debentures.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.betadrugslimited.com